Transcript Document

UNMET NEED
AHF/HF
Disease Awareness
Morbidity and Mortality: Patients with heart
failure are on a downward spiral, with frequent
hospitalizations and high mortality rates
•
With each acute event, myocardial injury may contribute to progressive left
ventricular dysfunction
•
Increasing frequency of acute events with disease progression leads to high
rates of hospitalization and increased risk of mortality
Chronic
decline
Cardiac
function and
quality of life
Acute
episodes
Disease progression
Adapted from Gheorghiade et al. Am J Cardiol 2005;96:11–17; Gheorghiade and Pang. J Am Coll Cardiol 2009;53:557–73
Resource and economic burden:
Extensive resource utilization for heart failure
Treating patients with HF is
RESOURCE INTENSIVE1
HOSPITAL
Median length of
hospitalization is
8 days‡2
48% of hospitalized
patients will require
admission to the ICU
for a median period
of 4 days‡2
The GREATEST
resource utilization
occurs within
6 months
of the
initial
hospitalization
Data from 1,892 European patients with acute heart failure in the European Society of Cardiology Heart Failure (ESC-HF) Pilot study;
HF=heart failure; ICU=intensive care unit;
1. Korves et al. J Med Econ 2012;15:925–37; 2. Maggioni et al. Euro J Heart Fail 2010;12:1076–84
for HF1
Lack of awareness:
The prevalence, symptoms and prognosis of
heart failure is under-recognized by the public
PEOPLE’S PERCEPTIONS OF HF
86% have heard of HF…
…but only 3% can identify
its signs and symptoms
>70% do not consider
HF
to be a serious condition
67% wrongly believe that
HF patients have a better
prognosis than cancer patients
HF=heart failure
Data from the Study on Heart failure Awareness and Perception in Europe (SHAPE), a survey of nearly 8,000 people from nine European countries (France, Germany,
Italy, The Netherlands, Poland, Romania, Spain, Sweden, UK). People aged between 25–45 and 65–85 years old were randomly selected. An equal distribution of
men and women, and people from urban and rural areas were chosen. Survey conducted in 2002.
Remme et al. Eur Heart J 2005;26:2413–21
Unmet therapeutic need:
There is a need for therapeutic advances in
acute heart failure
The evidence base for many commonly used acute HF
treatments is limited with no long-term benefits proven1
Class of
recommendation
Level of evidence†
(A–C)
I
B
Group
Medication
Diuretics
Loop diuretics
Vasodilators
Nitrates
IIa
B
Vasodilators
Sodium nitroprusside
IIb
B
Opiates
Morphine
IIa
C
Inotropes
Dobutamine
IIa
C
Limited evidence
is available to guide treatment1
†A=data derived from multiple randomized controlled trials (RCTs) or meta-analyses; B=data derived from a single RCT or large non-randomized studies; C=consensus
of opinion of experts and/or data from small studies, retrospective studies, or registries
1. McMurray et al. Eur Heart J 2012;33:1787–1847
Growing burden on Healthcare
Systems
Item Code:153048 Copyright © Novartis Pharma AG.